Patients Who Submitted Input to HTA Decisions for Ozempic
Health Canada Patient Input Program received submissions from 28 patients for Ozempic (semaglutide injection) during its CADTH review for type 2 diabetes. Inputs came from individual patients and groups, focusing on daily impacts like fatigue, mobility limits, and emotional strain from uncontrolled blood sugar.[1]
Key submitters included:
- Individual patients: 25 people living with type 2 diabetes shared personal stories. Common experiences involved severe tiredness, frequent infections, foot ulcers, and weight gain despite diet efforts. One patient described needing help to stand after meals; another noted isolation from family activities due to low energy.
- Patient groups: Diabetes Canada (3 submissions), Canadian Working Group on Normocaloric Nutrition and the Canadian Association of Psoriasis Patients (1 combined input), and the Canadian Organization for Rare Disorders (1 input on related complications).
Patients prioritized outcomes like sustained blood sugar control, weight loss, and fewer daily disruptions over strict A1C reductions. No submissions were received for heart failure indications in the same review.[1]
How Patient Input Shapes CADTH Reimbursement Decisions
CADTH incorporates these inputs into pCODR reports, weighing them against clinical data. For Ozempic, patient voices highlighted real-world tolerability issues (e.g., nausea persistence) and preferences for once-weekly dosing, influencing cost-effectiveness analyses for public drug plans.[1][2]
Patient Perspectives in Other HTA Bodies
- NICE (UK): For Ozempic's type 2 diabetes approval, 12 patient submissions via Rare Diseases UK and individual experts emphasized cardiovascular risk reduction and quality-of-life gains, supporting its recommendation despite high costs.[3]
- IQWiG (Germany): Limited patient input; one formal submission from Deutsche Diabetes-Hilfe noted gaps in long-term data for obese patients, leading to partial benefit assessments.[4]
- No centralized patient submissions recorded for EUnetHTA joint assessments, but national bodies like France's HAS referenced anonymous patient surveys on GI side effects.[5]
What Patients Commonly Report in Ozempic HTA Inputs
Across reviews, patients stress:
- Relief from "brain fog" and neuropathy pain.
- Challenges with injection site reactions or appetite suppression.
- Concerns over access barriers for non-diabetic obesity use.
These inputs often sway decisions toward broader eligibility when clinical trials underrepresent lived experiences.[1][3]
Where to Find Full Patient Submissions
Raw inputs are public on CADTH's website (search "semaglutide patient input"). Similar transparency exists for NICE via their evidence database.[1][2][3]
[1]: CADTH Patient Input for Semaglutide (Ozempic)
[2]: CADTH pCODR Ozempic Review
[3]: NICE Technology Appraisal TA917 Patient Input
[4]: IQWiG Benefit Assessment Semaglutide
[5]: HAS France Ozempic Transparency Committee